Patients with heart failure with improved ejection fraction benefit from the SGLT2 inhibitor dapagliflozin: Study

Group of the scientists working at the laboratory

With modern therapies for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their cardiac function during treatment. But despite this improvement in the ability of their hearts to pump, these patients with so called heart failure with improved ejection fraction (HFimpEF) remain at high risk for adverse outcomes.

A ton of Sony speakers are on sale at Amazon right now

Previous article

Uncovering the relationship between fatty liver disease and COVID-19

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations